Moreover, novel therapeutic platforms such as CAR-T cells targeting claudin 18.2 or other gastrointestinal-specific antigens are being actively explored in metastatic disease, showing early signs of safety and activity [74]. This evidence concerns the gene CLDN18 and metastatic neoplasm.